Osimertinib

Adenocarcinoma

Blueprint Medicines CorporationSmall moleculePhase 2Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

26 Active assets in the Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Mayo Clinic	Phase 4	BBB
Carboplatin Blueprint Medicines Corporation	Phase 4	BBB
Irinotecan University of Chicago	Phase 2	BBB
Icotinib Betta Pharmaceuticals Co., Ltd.	Phase 4	BB
Cyclophosphamide M.D. Anderson Cancer Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Osimertinib is also rated in:

non-small cell lung carcinomaActive

BB

Indicative · Phase 4

71 / 100

lung adenocarcinomaDormant

BB

Indicative · Phase 2

69 / 100

hepatocellular carcinomaActive

BB

Indicative · Phase 3

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.